Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

V disease and is administered by intramuscular injection. The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose of Synagis should be administered prior to commencement of the RSV season, which usually starts in the fall and runs through the spring. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least one percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

The pivotal trial for Synagis was called the IMpact trial and comprised a total of 1,502 children who were randomized (500 placebo, 1,002 Synagis) in a double-blind, placebo-controlled protocol where 1,486 children completed the study's follow-up.

In the IMpact trial, monthly prophylaxis with Synagis via intramuscular injections was associated with a 55-percent reduction in hospitalization as a result of RSV (p=<0.001). Reductions were observed in both children with bronchopulmonary dysplasia (38 percent reduction) and premature children without BPD (78 percent reduction). Approximately 50 percent of the
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Research ... the "Global Advanced Wound Care and Closure ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... wound care and closure market (types, applications, end ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds ... ablation device market will expand through 2023 ... atrial fibrillation (AF). The increasing acceptance of ... AF will spur adoption of premium-priced products ... advanced loop diagnostic catheters, cryoablation catheters and ...
(Date:8/20/2014)... SALT LAKE CITY , Aug. 20, 2014 /PRNewswire/ ... their revolutionary mobile diagnostic platform during a special event ... City, Utah , on September 5, 2014. The ... be LiveStreamed on the ApolloDx website, www.apollodx.com .  ... will transform diagnostic testing," said Jared Bauer , ...
Breaking Medicine Technology:Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... Oct. 15  Syndax Pharmaceuticals, Inc., a ... UK Intellectual Property Office allowed application GB0907347.9 ... covers the polymorph representing a preferred stable ... key claims covering the polymorph form B ...
... International, LLC today celebrates the official grand opening of its ... PA. The new facility not only preserves jobs in the ... staffing as the company grows. VWR is one ... with worldwide sales in excess of $3.5 billion, providing a ...
Cached Medicine Technology:Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat 2Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat 3VWR Opens New Global Headquarters in Radnor, PA 2VWR Opens New Global Headquarters in Radnor, PA 3
(Date:8/21/2014)... 21, 2014 Denver marketing agency ... for the American Lung Association in Colorado’s 2014 ... welcome Webolutions as a sponsor,” said Curt Huber, Chief ... Executive Director, American Lung Association in Colorado, “and we’re ... in this role they’ve defined.” , Webolutions has also ...
(Date:8/21/2014)... August 21, 2014 If chocolate is good ... will soon be very happy and healthy. Tracie is the ... Break ” contest. She and three of her coworkers will ... luxuriate at the world-famous Chocolate Spa® at The Hotel Hershey® ... third year working in the ambulatory surgery center at Connecticut ...
(Date:8/21/2014)... Rockville Centre, NY (PRWEB) August 21, 2014 ... injury law firm with over 25 years of experience ... dangerous prescription drugs and defective medical devices, announces the ... offer information to those women who believe they have ... The site offers valuable information about the severe adverse ...
(Date:8/21/2014)... Michael E. Steuer , local doctor ... to the Bluff City with recent philanthropy at local synagogue. ... the United States,” says friend and Rabbi David Julian of ... such as providing in-house for the needy and teaching Hebrew ... in the local synagogue. And to remain close with the ...
(Date:8/21/2014)... August 21, 2014 InSilico ... interventions and addressing the challenges of a ... OncoFinder, for signalome-wide pathway analysis. This ... cross-platform analysis of gene expression data obtained ... published in the journal Frontiers in Molecular ...
Breaking Medicine News(10 mins):Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:Connecticut Nurse Wins a Sweet Prize from California Casualty 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... INDIANAPOLIS, Sept. 14 In conjunction with today,s announcement ... to patients, Eli Lilly and Company (NYSE: ... Center of Excellence and its five business units: oncology, ... These leaders will provide improved line of sight to ...
... in dementia care is not so much related to equipment ... communication problems and misunderstandings. This is shown in a new ... Sweden. Dementia not only affects the memory and other ... to walk. ,The symptoms of dementia are very individual ...
... , AHIP to leverage MedAssurant,s datasets and ... affordability of healthcare. , , WASHINGTON, ... Inc., announced today that MedAssurant, through its healthcare data analytics ... quality and effectiveness of treatments. , , ...
... boosting the odds, experts say, , MONDAY, Sept. 14 (HealthDay ... the odds that a child will develop asthma or allergies, ... spent more than 1,000 hours swimming in chlorinated pools, either ... of having asthma than did teens who primarily swam in ...
... , , NCCN is ... forum to discuss the regulatory and operational aspects of research ... improvements can be made. Scheduled for October 26 - 27 ... and panel discussions on topics that challenge the conduct of ...
... Schizophrenia is a major public health problem. Affecting almost ... economic and social toll in addition to the distress, ... disease. Elements of the disease are present from birth, ... becomes fully expressed in early adulthood with long-lasting implications ...
Cached Medicine News:Health News:Lilly Names New Business Leaders 2Health News:Lilly Names New Business Leaders 3Health News:Lilly Names New Business Leaders 4Health News:Lilly Names New Business Leaders 5Health News:Lilly Names New Business Leaders 6Health News:Lilly Names New Business Leaders 7Health News:Lilly Names New Business Leaders 8Health News:Communication problems in dementia care cause physical strain 2Health News:MedAssurant to Support AHIP's Research Capabilities 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 3Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3Health News:The future of schizophrenia 2Health News:The future of schizophrenia 3Health News:The future of schizophrenia 4Health News:The future of schizophrenia 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: